AL-S Pharma Appoints Harry Welten as Chief Executive Officer
News 14.10.2026 ZURICH, Switzerland – October 14, 2026 – AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael...